scholarly journals PATCHing platelet data to improve transfusion

Blood ◽  
2020 ◽  
Vol 135 (16) ◽  
pp. 1309-1310
Author(s):  
Eric A. Gehrie ◽  
Aaron A. R. Tobian
Keyword(s):  
Adverse Effects ◽  
Cerebral Hemorrhage ◽  
Platelet Transfusion ◽  
Antiplatelet Agents ◽  
Patch Trial

The Platelet Transfusion in Cerebral Hemorrhage (PATCH) trial, a trial of platelet transfusion in patients on antiplatelet agents with cerebral hemorrhage, suggested that platelets worsened outcomes. Reanalysis of the data by the investigators revealed that despite randomization, some, if not all, of the adverse effects of platelets reflected worse baseline hemorrhage in patients in the platelet arm.

Managing adverse effects and drug–drug interactions of antiplatelet agents

2011 ◽  
Vol 8 (10) ◽  
pp. 592-600 ◽  
Author(s):  
Arun Kalyanasundaram ◽  
A. Michael Lincoff
Keyword(s):  
Adverse Effects ◽  
Drug Interactions ◽  
Antiplatelet Agents

scholarly journals Incidence and severity of adverse effects related to platelet transfusion: a narrative review of the literature and the recent hemovigilance data of Japan

2021 ◽  
Vol 0 ◽  
pp. 0-0
Author(s):  
Tomohiko Sato ◽  
Nelson Hirokazu Tsuno ◽  
Naoko Goto ◽  
Takeshi Hagino ◽  
Tetsunori Tasaki
Keyword(s):  
Adverse Effects ◽  
Platelet Transfusion ◽  
Narrative Review ◽  
Review Of The Literature

Tu1361 Platelet Transfusion for Acute GI Bleeding in Patients Taking Antiplatelet Agents: Is There Benefit or Harm?

2016 ◽  
Vol 150 (4) ◽  
pp. S883-S884 ◽  
Author(s):  
Liam Zakko ◽  
Tarun Rustagi ◽  
Maura Douglas ◽  
Loren Laine
Keyword(s):  
Platelet Transfusion ◽  
Antiplatelet Agents ◽  
Gi Bleeding

Impact of platelet transfusion on hematoma expansion in patients receiving antiplatelet agents before intracerebral hemorrhage

2010 ◽  
Vol 32 (7) ◽  
pp. 706-710 ◽  
Author(s):  
Andrew F. Ducruet ◽  
Zachary L. Hickman ◽  
Brad E. Zacharia ◽  
Bartosz T. Grobelny ◽  
Peter A. DeRosa ◽  
...  
Keyword(s):  
Intracerebral Hemorrhage ◽  
Platelet Transfusion ◽  
Antiplatelet Agents ◽  
Hematoma Expansion

Antiplatelet Therapy in Older Patients Post-Myocardial Infarction

2022 ◽  
Vol 37 (1) ◽  
pp. 17-23
Author(s):  
Hindu Rao ◽  
Paul Phan ◽  
Megan Eclevia ◽  
Laura Tsu
Keyword(s):  
Myocardial Infarction ◽  
Adverse Effects ◽  
Older Patients ◽  
Treatment Options ◽  
Antiplatelet Agents ◽  
Post Myocardial Infarction ◽  
Older Patient ◽  
Antiplatelet Treatment ◽  
Specific Factors

This case study reviews appropriate antiplatelet treatment options for an older patient post-myocardial infarction and stent placement. This case investigates the benefits and risks associated with antiplatelet agents in older people and what patient- and drug-specific factors, such as adverse effects and drug interactions, to consider when choosing treatment.

Cardiovascular drugs

2019 ◽  
pp. 177-204
Author(s):  
Carl Waldmann ◽  
Andrew Rhodes ◽  
Neil Soni ◽  
Jonathan Handy
Keyword(s):  
Critical Care ◽  
Intensive Care ◽  
Adverse Effects ◽  
Critically Ill ◽  
Phosphodiesterase Inhibitors ◽  
Antiplatelet Agents ◽  
Cardiovascular Drugs ◽  
Haemodynamic Instability ◽  
Adrenergic Agonists

Haemodynamic instability is one of the main reasons for admission to critical care. Often patients will require medication to provide cardiovascular support. This chapter discusses cardiovascular drugs and includes discussion on β‎-adrenergic agonists, phosphodiesterase inhibitors, vasodilators, vasopressors, antiarrhythmics in intensive care, chronotropes, antianginal agents, antiplatelet agents, diuretics and the critically ill, and levosimendan. These medications are part of the daily practise in intensive care. Knowledge of the indications, interactions, and adverse effects is essential.

Sign in / Sign up

Export Citation Format

Share Document